data access
Dotaz
Zobrazit nápovědu
1 online zdroj
- MeSH
- data mining MeSH
- sběr dat metody MeSH
- ukládání a vyhledávání informací * MeSH
- Publikační typ
- dataset MeSH
- periodika MeSH
- Konspekt
- Věda. Všeobecnosti. Základy vědy a kultury. Vědecká práce
- NLK Obory
- věda a výzkum
... 82 -- Úvod do jazyka SQL v Accessu 82 -- Návrh dotazu v Accessu 83 -- Typy dotazů v Accessu 84 -- Proč ... ... 85 -- Jazyk Access SQL 86 -- Syntaktické konvence 86 -- Komponenta DDL jazyka Access SQL 88 -- Příkaz ... ... systémy 116 -- Systémy pro správu databází 118 -- Databázový systém Jet 118 -- Jazyky pro definici dat ... ... 120 -- Jazyk pro definici dat v systému Jet 120 -- Jazyky pro manipulaci s daty 121 -- Jazyk pro manipulaci ... ... s daty v systému Jet 122 -- Hostitelské jazyky 123 -- Architektura klient/server 123 -- Kapitola 8 - ...
Vyd. 1. 250 s. : il. ; 23 cm
Vytváření databází v grafickém prostředí Accessu je natolik nenáročné a uživatelsky atraktivní, že uživatelům a často i zkušeným programátorům zahaluje důležité zásady konstrukce databází o více tabulkách a svádí k vytváření databází bez potřebné analýzy a promyšleného návrhu. Může za to i většina knih, které se vesměs zabývají podrobně uživatelským rozhraním a opomíjejí vysvětlit nezbytné zákonitosti relačního systému, který stojí v pozadí. Následky nevhodné struktury databáze však dolehnou později, kdy se projeví komplikovaným získáváním dat, překážkami při vkládání nových dat nebo dokonce ztrátou dat. Tato kniha neprobírá od všeho něco, ale soustřeďuje se na skutečně potřebná klíčová témata, je stručná a k věci. Je \"vyšší školou\" Accessu a jeho zkušeným uživatelům přibližuje namnoze přehlížené techniky, potřebné k úspěšné tvorbě aplikací v tomto populárním databázovém programu. Teorie je vysvětlena na ukázkové aplikaci a kniha obsahuje několik užitečných příloh. Vytváříte-li databáze nebo dotazy, přečtěte si tuto knihu.
- Klíčová slova
- informační technologie, Microsoft Access,
... The legislative framework governing personal health data 65 -- Data accessibility across OECD countries ... ... and access to de-identified data 84 -- Foreign applicants for access to data 87 -- Data sharing challenges ... ... about researcher access to data 107 -- Public opinion about data uses 110 -- Public communication: Lesson ... ... processors promotes both data security and access to data 132 -- References ,, 134 -- Chapter 6. ... ... Sharing and accessibility of health data for approved statistical and research uses 67 -- HEALTH DATA ...
OECD health policy studies, ISSN 2074-3181
197 stran : ilustrace ; 28 cm
- MeSH
- dokumentace MeSH
- dostupnost zdravotnických služeb MeSH
- důvěrnost informací MeSH
- ekonomika a organizace zdravotní péče MeSH
- integrované poskytování zdravotní péče MeSH
- osobní údaje MeSH
- veřejné zdravotnictví - informatika MeSH
- zdravotní politika MeSH
- zdravotnické informační systémy MeSH
- Konspekt
- Veřejné zdraví a hygiena
- NLK Obory
- veřejné zdravotnictví
- ekonomie, ekonomika, ekonomika zdravotnictví
- NLK Publikační typ
- studie
Objectives: Analysis of participation in drug costs by seniors in the Czech Republic in connection with seniors' access to pharmacotherapy. Materials and methods: Quota-sampled guided interview with 450 respondents visiting pharmacy; ratio of men and women approximately 1:2; age over 60 years; 3 regions of the Czech Republic. Results: Respondent's income was retirement pension in 80 %. More than 55% of respondents did not reach the official state average. Respondents used altogether 1,650 medicines on physician's prescription in the last four weeks. Overall co-payment for medicines was 38,778 CZK, i.e. 86 CZK per patient. Only 27% of respondents used fully reimbursed products. Respondents used together 273 OTC drugs (over-the-counter drugs, e.g. non prescription drugs) in value of 16,540 CZK, i.e. 37 CZK per patient. Average respondent spent on medicines 123 CZK in the last four weeks, i.e. 1.5% of the official state average income. There were respondents, about 10%, searching for the level of co-payment in several pharmacies and more than 8% of respondents had to refuse dispensation of medicines due to co-payment. Conclusions: Our study demonstrates that there are patients who may fail to gain access to medication due to co-payment in the Czech Republic. The financial participation in health care costs is generally low in the Czech Republic (8.8% of total health expenditures) but there were differences in co-payment levels in patients ranging from 1 CZK to thousands CZK. In our opinion problem might be in the absence of any instrument limiting the highest individual participation as it is for example in 12-month period in Sweden. In our study co-payments were lower in smaller communities that may be due to better communication between physicians and patients or physicians and pharmacists. We found a critical ethical problem in different levels of co-payment of concrete product.
- MeSH
- dostupnost zdravotnických služeb ekonomika zákonodárství a právo MeSH
- financování organizované využití MeSH
- interpretace statistických dat MeSH
- náklady na léky statistika a číselné údaje trendy zákonodárství a právo MeSH
- poplatky farmaceutické normy statistika a číselné údaje zákonodárství a právo MeSH
- poplatky lékařské statistika a číselné údaje zákonodárství a právo MeSH
- senioři statistika a číselné údaje MeSH
- Check Tag
- senioři statistika a číselné údaje MeSH
- Publikační typ
- rozhovory MeSH
- Geografické názvy
- Česká republika MeSH
[1. vyd.] 14 s. : obr., tab. ; 30 cm
Background: Inter-organizational healthcare businesses are ruled by a huge set of policies: legal policies, organizational policies, medical policies, ethical policies, etc., which are quite static, patients policy and process, social and environmental conditions, which are highly dynamic. In the context of a business case, those diff erent policies must be harmonized to enable privilege management and access control decisions. Objectives: The authors off er a methodology to achieve interoperability through policies harmonization in a privilege management and access control solution for EHR systems, to be later on implemented in a cancer care network using HL7 specifications. Methods: To meet the objective, the authors make use of a system-theoretical, architecture-centric, ontology-based approach to formally representing the aforementioned polices for harmonization. Results: Because of its fl exibility and generality, a policydriven RBAC model is used to formally represent all the other access control models such as MAC, DAC, RBAC, ABAC, HL7 Data Segmentation and Labeling Services. All the policies deployed in the context of an inter-organizational collaboration for cancer care can be formalized and then harmonized. Conclusions: The authors provide an implementation independent methodology to enable policies harmonization in EHR systems. The methodology described in the paper is independent on the maturity of organizations’ privilege management and access control system. Furthermore, it does not hamper organizations progressing to more advanced solutions over the time. Even dynamic policies can be harmonized at run time, allowing advancement towards a patient-centered care.
The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising trial design and delivery for speed and efficiency; ii) drug development for patients with rare CFTR mutations. We propose some strategies to tackle the challenges ahead and highlight areas where further thought is needed. We see this as the start of a process rather than the end and hope herewith to engage the wider community in seeking solutions to improved treatments for all patients with CF.
- MeSH
- cystická fibróza farmakoterapie genetika MeSH
- klinické zkoušky jako téma * metody normy MeSH
- lidé MeSH
- modulátory membránového transportu farmakologie MeSH
- mutace MeSH
- objevování léků * metody trendy MeSH
- protein CFTR genetika MeSH
- vyvíjení léků * organizace a řízení normy MeSH
- výzkumný projekt normy MeSH
- zlepšení kvality MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The Pan European Phenology (PEP) project is a European infrastructure to promote and facilitate phenological research, education, and environmental monitoring. The main objective is to maintain and develop a Pan European Phenological database (PEP725) with an open, unrestricted data access for science and education. PEP725 is the successor of the database developed through the COST action 725 "Establishing a European phenological data platform for climatological applications" working as a single access point for European-wide plant phenological data. So far, 32 European meteorological services and project partners from across Europe have joined and supplied data collected by volunteers from 1868 to the present for the PEP725 database. Most of the partners actively provide data on a regular basis. The database presently holds almost 12 million records, about 46 growing stages and 265 plant species (including cultivars), and can be accessed via http://www.pep725.eu/ . Users of the PEP725 database have studied a diversity of topics ranging from climate change impact, plant physiological question, phenological modeling, and remote sensing of vegetation to ecosystem productivity.
- MeSH
- faktografické databáze * MeSH
- roční období * MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
- MeSH
- dostupnost zdravotnických služeb MeSH
- kardiovaskulární nemoci epidemiologie MeSH
- mortalita epidemiologie MeSH
- poskytování zdravotní péče MeSH
- socioekonomické faktory MeSH
- Publikační typ
- hodnotící studie MeSH
- Geografické názvy
- Spojené království MeSH
BACKGROUND: Cardiotocography (CTG) is a monitoring of fetal heart rate and uterine contractions. Since 1960 it is routinely used by obstetricians to assess fetal well-being. Many attempts to introduce methods of automatic signal processing and evaluation have appeared during the last 20 years, however still no significant progress similar to that in the domain of adult heart rate variability, where open access databases are available (e.g. MIT-BIH), is visible. Based on a thorough review of the relevant publications, presented in this paper, the shortcomings of the current state are obvious. A lack of common ground for clinicians and technicians in the field hinders clinically usable progress. Our open access database of digital intrapartum cardiotocographic recordings aims to change that. DESCRIPTION: The intrapartum CTG database consists in total of 552 intrapartum recordings, which were acquired between April 2010 and August 2012 at the obstetrics ward of the University Hospital in Brno, Czech Republic. All recordings were stored in electronic form in the OB TraceVue®;system. The recordings were selected from 9164 intrapartum recordings with clinical as well as technical considerations in mind. All recordings are at most 90 minutes long and start a maximum of 90 minutes before delivery. The time relation of CTG to delivery is known as well as the length of the second stage of labor which does not exceed 30 minutes. The majority of recordings (all but 46 cesarean sections) is - on purpose - from vaginal deliveries. All recordings have available biochemical markers as well as some more general clinical features. Full description of the database and reasoning behind selection of the parameters is presented in the paper. CONCLUSION: A new open-access CTG database is introduced which should give the research community common ground for comparison of results on reasonably large database. We anticipate that after reading the paper, the reader will understand the context of the field from clinical and technical perspectives which will enable him/her to use the database and also understand its limitations.
- MeSH
- Apgar skóre MeSH
- distres plodu diagnóza MeSH
- dospělí MeSH
- faktografické databáze * MeSH
- fetální krev chemie MeSH
- kardiotokografie * MeSH
- koncentrace vodíkových iontů MeSH
- lidé MeSH
- počítačové zpracování signálu * MeSH
- porod MeSH
- poruchy acidobazické rovnováhy MeSH
- přístup k informacím * MeSH
- srdeční frekvence plodu * MeSH
- těhotenství MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH